Truscreen Group Ltd
ASX:TRU
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| NZ |
|
Truscreen Group Ltd
NZX:TRU
|
12m NZD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
173.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
116.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
106.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
48.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD |
Loading...
|
Market Distribution
| Min | -127.6% |
| 30th Percentile | 37.1% |
| Median | 51% |
| 70th Percentile | 64.7% |
| Max | 107.2% |
Other Profitability Ratios
Truscreen Group Ltd
Glance View
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Truscreen Group Ltd is 28.5%, which is below its 3-year median of 30.1%.
Over the last 3 years, Truscreen Group Ltd’s Gross Margin has increased from 23.1% to 28.5%. During this period, it reached a low of 23.1% on Sep 30, 2022 and a high of 37.6% on Sep 30, 2024.
